These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months. Ramirez CB, Doria C, di Francesco F, Iaria M, Kang Y, Marino IR. J Surg Res; 2007 Apr; 138(2):198-204. PubMed ID: 17292404 [Abstract] [Full Text] [Related]
5. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up. Ciancio G, Burke GW, Gaynor JJ, Roth D, Sageshima J, Kupin W, Tueros L, Hanson L, Rosen A, Ruiz P, Miller J. Transplantation; 2008 Jul 15; 86(1):67-74. PubMed ID: 18622280 [Abstract] [Full Text] [Related]
7. A Prospective Randomized, Comparative Trial of High-Dose Mizoribine Versus Mycophenolate Mofetil in Combination With Tacrolimus and Basiliximab for Living Donor Renal Transplant: A Multicenter Trial. Ishida H, Takahara S, Amada N, Tomikawa S, Chikaraishi T, Takahashi K, Uchida K, Akiyama T, Tanabe K, Toma H, Study Group for the Antimetabolite Comparison of Trial (AMCT). Exp Clin Transplant; 2016 Oct 15; 14(5):518-525. PubMed ID: 27733107 [Abstract] [Full Text] [Related]
9. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group. Gruessner RW. Clin Transplant; 1997 Aug 15; 11(4):299-312. PubMed ID: 9267719 [Abstract] [Full Text] [Related]
10. Steroid-avoidance immunosuppression regimen in live-donor renal allotransplant recipients: a prospective, randomized, controlled study. Nematalla AH, Bakr MA, Gheith OA, Elagroudy AE, Elshahawy el-M, Aghoneim M. Exp Clin Transplant; 2007 Dec 15; 5(2):673-9. PubMed ID: 18194120 [Abstract] [Full Text] [Related]
11. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis. Stratta RJ, Alloway RR, Hodge E, Lo A, Pancreas Investigators Vital Outcomes Trial (PIVOT) Study Group. Clin Transplant; 2002 Feb 15; 16(1):60-8. PubMed ID: 11982617 [Abstract] [Full Text] [Related]
14. Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in liver transplantation. Becker T, Foltys D, Bilbao I, D'Amico D, Colledan M, Bernardos A, Beckebaum S, Isoniemi H, Pirenne J, Jaray J, MARSILEA Study Group. Transplantation; 2008 Dec 27; 86(12):1689-94. PubMed ID: 19104406 [Abstract] [Full Text] [Related]
18. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. Stegall MD, Wachs ME, Everson G, Steinberg T, Bilir B, Shrestha R, Karrer F, Kam I. Transplantation; 1997 Dec 27; 64(12):1755-60. PubMed ID: 9422416 [Abstract] [Full Text] [Related]
20. Randomized trial of cyclosporine and tacrolimus therapy with steroid withdrawal in living-donor renal transplantation: 5-year follow-up. Lee YJ, Kim B, Lee JE, Kim YG, Kim DJ, Kim SJ, Joh JW, Oh HY, Huh W. Transpl Int; 2010 Feb 27; 23(2):147-54. PubMed ID: 19744223 [Abstract] [Full Text] [Related] Page: [Next] [New Search]